Trial Profile
A randomised double-blind pilot study comparing flecainide CR [controlled release] and placebo in the early treatment of patients with a documented first episode of atrial fibrillation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Flecainide (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors 3M Pharmaceuticals
- 18 Dec 2006 New trial record.